Hirunwiwatkul P.Supawatjariyakul W.Jariyakosol S.Apinyawasisuk S.Sriratanaban J.Chongpison Y.Jagota P.Aui-Aree N.Witthayaweerasak J.Setthawatcharawanich S.Kitthaweesin K.Chirapapaisan N.Chaimongkoltrakul P.Laowanapiban P.Hansapinyo L.Panpitpat S.Kurathong S.Nimworaphan J.Thitiwichienlert S.Vanikieti K.Samipak N.Srimanan W.Mekhasingharak N.Chaitanuwong P.Mahidol University2023-05-192023-05-192023-03-01PLoS ONE Vol.18 No.3 March (2023)https://repository.li.mahidol.ac.th/handle/20.500.14594/82143Purpose To compare Thais’ health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment. Design Prospective-observational study. Participants BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021. Methods Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded. Results 184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13 ±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month. Conclusion Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.MultidisciplinaryArticleSCOPUS10.1371/journal.pone.02831112-s2.0-851502832161932620336920965